DARATUMUMAB + BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE)/TRANSPLANT-DEFERRED (TD) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): PHASE 3 CEPHEUS TRIAL CYTOGENETIC SUBGROUP ANALYSIS NJ Bahlis; SZ Usmani; T Facon; S Zweegman; C Venner; M Braunstein; L Pour; J Marti; A Maiolino; V Hungria;

DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (DVRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): SUBGROUP ANALYSIS OF TRANSPLANT- INELIGIBLE (TIE) PATIENTS IN THE PHASE 3 CEPHEUS STUDY T Facon; S Zweegman; V Hungria; NJ Bahlis; CP Venner; M Braunstein; L Pour; J Marti; A Maiolino; SZ Usmani;

TREATMENT PATTERNS AND OUTCOMES IN THE SECOND AND THIRD LINES AND AFTER TRIPLE-CLASS EXPOSURE: SUBANALYSIS OF THE LATIN AMERICAN MULTIPLE MYELOMA REGISTRY STUDY (MYLACRE) A Maiolino; K Galvez; G Remaggi; N Schutz; R Bittencourt; V Hungria; C Colaco; E Crusoe; W Tobias; R Gaiolla;